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Objective: To evaluate the inﬂuence of tranexamic acid on epidermal permeability barrier function in
rosacea and its potential mechanisms.
Methods: A randomized, vehicle controlled, split-face study was performed on 30 rosacea patients. This
study involved 2 weeks of 3% tranexamic acid solution treatment and vehicle control treatment. Skin
physiological parameters, including skin surface pH, stratum corneum hydration, and transepidermal
water loss, were measured. The expression of protease-activated receptor 2 (PAR-2) in rosacea and
normal skin samples was assessed with immunohistochemical staining. The expression of PAR-2 in
HaCaT keratinocytes was determined using reverse transcription polymerase chain reaction after stim-
ulation with tranexamic acid. Changes of intracellular calcium induced by PAR-2 activation were
measured using Fluo-4 NW calcium assay.
Results: Individuals with rosacea expressed a higher baseline level of PAR-2 compared with normal skin.
Tranexamic acid improved the permeability barrier function in rosacea patients and inhibited calcium
mobilization in keratinocytes induced by PAR-2 activation. The PAR-2 expression was not altered by
tranexamic acid stimulation.
Conclusion: Topical tranexamic acid could improve the epidermal permeability barrier function and
clinical signs of rosacea, likely resulting from inhibition of PAR-2 activation and consequent calcium
inﬂux. Thus, tranexamic acid could serve as an adjuvant therapy for rosacea.
Copyright © 2015, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Rosacea is a common inﬂammatory facial disorder with compro-
mised epidermal permeability barrier function. The common
manifestations of rosacea include recurrent erythema, telangiec-
tasia, inﬂammatory papules and pustules on the mid face, or rhi-
nophyma in severe cases. The current therapies for rosacea have
certain limitations, and prevention of relapse requires a long-term
maintenance therapy.1 The treatments are often short of targets,
largely due to its unknown pathogenesis.2,3 Recent studies have
suggested that protease-activated receptor 2 (PAR-2) could be
involved in the pathogenesis of rosacea. PAR-2 is a G-protein-
coupled 7-transmembrane domain receptor, which mediates
inﬂammation in various tissues upon activation by serine proteasesy have no ﬁnancial or non-
atter or materials discussed
logy, Peking University First
).
cal Association. Published by Elsev(SPs) such as kallikrein.4,5 Consistently, the activities of SPs are
increased in rosacea. SPs degrade the epidermal antimicrobial
peptide to its active form, cathelicidin LL-37. The latter can mediate
vascular action and inﬂammation, which are features of rosacea.6e8
Compromised epidermal permeability barrier function is
another feature of rosacea.9 While rosacea exhibits a higher level of
transepidermal water loss, improvement of permeability barrier
function alleviates rosacea.10 Whether the defective permeability
barrier is the cause or the resultant of rosacea is not clear, it is likely
linked to the increased SP activity. Previous studies showed that the
increased SP activity is associated with certain dermatoses, such as
atopic dermatitis, accompanied by defective permeability barrier.11
Conversely, inhibition of SP activity by either lowering stratum
corneum pH or topical SP inhibitors, improves epidermal perme-
ability barrier homeostasis in barrier-disrupted skin. As an SP in-
hibitor, tranexamic acid has been proved to accelerate the
restoration of the damaged skin barrier. In this study, we chose
tranexamic acid as a candidate treatment for rosacea, since it can
act as an inhibitor of SP and accelerate the recovery of the damaged
skin barrier resulting from tape stripping, acetone, sodium dodecylier Taiwan LLC. All rights reserved.
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pothesize that in rosacea, activation of PAR-2 by SP results in
inﬂammation and defective permeability barrier.
In the present study, we determined whether inhibition of SP
activity by tranexamic acid improves rosacea in vivo and affects
calcium mobilization induced by PAR-2 activation in vitro, which
may further prove the importance of barrier abnormality in the
etiology of rosacea, and indicate a new direction for rosacea
treatment.
Methods
Participants
The study was conducted following the principles outlined in the
Declaration of Helsinki. The protocol was read and approved by the
Ethics Committee of Peking University First Hospital, Beijing, China.
Written informed consent was obtained from all patients prior to
the study. Thirty patients aged 18e65 years were recruited ac-
cording to the diagnostic criteria of rosacea.1 The exclusion criteria
included people with facial acne, steroid-dependent dermatitis, or
other skin or systemic diseases that might inﬂuence skin assess-
ment; using antirosacea drugs (including antibiotics), steroids, or
vasodilating agents topically during the past 2 weeks or orally
during the past 1 month; allergic to the test ingredients; during
gestation or lactation. A randomized, vehicle controlled, split-face
study was performed on 30 rosacea patients. One side of each pa-
tient's face was topically treated with 5% tranexamic acid solution
twice daily for 2 weeks while the vehicle-treated side served as a
control. During the study, no other topical or systemic agents were
allowed. This study was conducted in MarcheMay 2011, in Beijing,
China.
Physiological assessment
After facial cleansing at each visit, the patients were kept in a test
room with a controlled temperature (20e22C) and humidity
(40e60%) for 30 minutes before physiological measurements.
Corneometer CM825 (COURAGEþKHAZAKA electronic GmbH,
K€oln, Germany) was used to measure the water content in the
stratum corneum. Tewameter TM300 and pH meter pH900 (both
from COURAGEþKHAZAKA electronic GmbH, K€oln, Germany) were
used to measure transepidermal water loss and pH value, respec-
tively. Chromameter CM2600d (Konica Minolta, Inc., Tokyo, Japan)
was used for the measurement of Chroma, an indicator for the
severity of erythema14; VISIA Image System (Canﬁeld Scientiﬁc, Inc.
Fairﬁeld, NJ, USA) was used for image analysis.
Cell culture and reagents
Immortalized human keratinocyte cell line HaCaT were purchased
from the China Center for Type Culture Collection (Wuhan, China)
and cultured 1% penicillin-streptomycin at 37 in Dulbecco's
Modiﬁed Eagle's medium (Gibco, Langley, OK, USA) supplemented
with 10% fetal bovine serum and C in a humidiﬁed CO2 incubator
(95% air, 5% CO2). For stimulation, cells were cultured in 12-well
plates (Corning, Inc., Corning, NY, USA). At 60e70% conﬂuence,
culture medium was replaced with serum-free medium, followed
by incubation with tranexamic acid (200 mg/mL) for an additional
24 hours. Then the keratinocytes were harvested for analysis.
MTT assay
Three-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bro-
mide (MTT, Sigma-Aldrich, St. Louis, MO, USA) assay was used todetermine the viability of HaCaT cells and the appropriate con-
centration of tranexamic acid to treat cells.15 Tranexamic acid of
400 mg/mL, 200 mg/mL, 100 mg/mL, and 50 mg/mL diluted in phos-
phate-buffered saline (PBS) were used to treat cells for 24 hours.16
After incubation with MTT for 4 hours, the optical density of each
well was read at 540 nm using a microplate reader.
Histology and immunohistochemistry
Four mm thin-sections of formalin-ﬁxed, parafﬁn-embedded skin
samples were stained using immunohistochemistry. Brieﬂy, ﬁxed
sections were deparafﬁnized, rehydrated and washed in PBS (2  5
minutes). For antigen retrieval, the sections were put into 10mM
citrate buffer (pH 6.0) and boiled for 15 minutes. After cooling at
room temperature, sections were treated with 3% H2O2for 15 mi-
nutes, and incubated with primary antibodies (rabbit polyclonal
antihuman, Santa Cruz Biotechnology, Santa Cruz, CA, USA, 1:200)
overnight at 4C. Secondary antibodies were polyperoxidase-
antimouse/rabbit immunoglobulin G. Staining color was devel-
oped using 3,30-diaminobenzidine for 1e3 minutes. The reaction
was stopped with distilled water while being observed under a
microscope. Harris hematoxylin was used for counterstaining.
Slides were examined at 200  and 400  magniﬁcation. Images
were evaluated using the Leica microscope with imaging software
(Leica Application Suite, Leica Microsystems Limited, Switzerland).
RNA isolation, cDNA synthesis, and quantitative real-time
polymerase chain reaction
After stimulation for 24 hours, keratinocytes were washed with
PBS, and RNA was isolated using RNeasy 96 Kit (Qiagen, Hilden,
Germany) according to the manufacturer's instructions. For cDNA
synthesis RNAwas reverse-transcribed with iScript cDNA Synthesis
Kit (Bio-Rad, Hercules, CA, USA) and real-time polymerase chain
reaction (PCR) was carried out with ViiA 7 Real-time PCR system
(Applied Biosystem Life Technology, USA) according to the manu-
facturer's instructions. The relative expression of the target genes
were calculated by comparing with the housekeeping gene GAPDH
using a formula described previously.17 The primers used are PAR-
2：forward 50-ACATGGCAACAACTGGGTCT-30；reverse, 50-CGAT
CACCCAGTACCTCTGC-30. GAPDH: forward 50-TGACGTGCCGCCTG
GAGAAA-30; R50-AGTGTAGCCCAAGATGCCCTTCAG-30. All real-time
PCR experiments were performed at least in triplicate and the
speciﬁcity of the reactions was conﬁrmed by sequencing the PCR
products.
Fluo-4 NW calcium assay to detect the in-cell calcium signaling
of PAR-2 activation in HaCat
HaCaT cells were cultured on the chamber slice（Lab-Tek Nunc,
Thermo Scientiﬁc, USA）and used at 50% conﬂuent. After incuba-
tion with basal medium or tranexamic acid for 24 hours, the me-
diumwas removed and washed with Ca2þ free assay buffer. To each
well 100 mL of the dye loading solution was added. The plates were
incubated at 37C for 30 minutes, then at room temperature for an
additional 30 minutes. As a PAR-2 agonist 100nM trypsinwas used;
ﬂuorescence images were measured and recorded using a laser
confocal microscope（Leica TCS SP5 microsystem, Germany）for
excitation at 488 nm.
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 5
(GraphPad Software Inc., San Diego, CA, USA). Calculations are
based on the means of independent experiments (each individual
S. Zhong et al. / Dermatologica Sinica 33 (2015) 112e117114experiment with 3e4 replicates) Comparison between the control
and the treated side was performed using Student t test and
ManneWhitney test, while comparison between prior-treatment
and post-treatment was performed by paired t test and Wilcoxon
signed ranks test. A p value < 0.05 was considered statistically
signiﬁcant.
Results
Inﬂuence of tranexamic acid on skin barrier function in rosacea
patients
The mean age of the rosacea patients was 39.34 ± 11.43 years. Forty
percent (12/30) of these patients weremale and 60.0% (18/30) were
female. As shown in Figure 1, the baseline stratum corneum func-
tions on the control side were similar to the treated side. After 2
weeks of treatment, all skin biophysical parameters on the treated
side were signiﬁcantly improved compared to baseline, while the
vehicle treatment induced no changes in stratum corneum func-
tions. In parallel with the improvement of stratum corneum func-
tions, clinical sign and symptoms were also improved dramatically
after treatments with topical tranexamic acid (Figure 2 and
Table 1). These results demonstrate that topical tranexamic acid
improves both stratum corneum functions, and clinical signs and
symptoms of rosacea.
Rosacea patients express high level of PAR-2
Since activation of PAR-2 is involved in the pathogenesis of rosa-
cea,18 we next assessed the expression of PAR-2 in rosacea patients
with immunohistochemical staining. As seen in Figures 3B and 3D,
PAR-2 was weakly expressed in the nuclei and cytoplasm of the
normal epidermis whereas a more intense staining of PAR-2 was
shown in both nuclei and cytoplasm in rosacea patients (Figures 3A
and 3C). These results indicate that the epidermal PAR-2 expression
is elevated in rosacea patients.Figure 1 Changes in physiological parameters. (A) Stratum corneum biophysical propertie
treated side, Chroma a value decreased signiﬁcantly after 2-week treatment (p < 0.05), indic
2-week treatment, transepidermal water loss; (C) and skin surface pH value decreased sign
barrier function of rosacea was improved signiﬁcantly (p < 0.05). The statistical signiﬁcancTranexamic acid inhibits calcium mobilization induced by PAR-
2 activation
Previous studies have shown that activation of PAR2 by protease
stimulates Ca2þ.19 We then determined whether tranexamic acid
inhibits Ca2þ mobilization induced by PAR2 activation, providing a
potential mechanism whereby tranexamic acid improves rosacea.
The optimal concentration of tranexamic acid in keratinocyte cul-
tures was determined using MTT assay. Our results showed that
200 ug/L caused no changes in cell viability. Therefore, 200 mg/L of
tranexamic acid was used in all our studies in vitro. As seen in
Figure 4, the addition of trypsin, a potent activator of PAR2, HaCaT
cells induced an immediate increase in the intensity of ﬂuorescence
(blue line in Figure 4A and top panel in Figure 4B), indicating the
stimulation of Ca2þ mobilization. The maximum signal
(975.88 ± 120.27) was obtained 40 seconds after the addition of
trypsin. However, following the treatment of cells with 200 mg/L
tranexamic acid for 24 hours，trypsin-induced peak signal of
ﬂuorescencewasmuch lower (464.06 ± 72.35, red line in Figure 4A)
than without tranexamic acid. Moreover, the appearance of peak
signal was delayed by 120 seconds (Figure 4A, p < 0.05). To deter-
mine whether the tranexamic acid-induced inhibition of Ca2þ
mobilization is due to inhibition of PAR-2 production, the expres-
sion levels of PAR-2 mRNA were measured in HaCaT cells after
tranexamic acid treatment. As shown in Figure 5, incubation of
HaCaT cells with tranexamic acid did not affect the expression
levels of PAR-2 mRNA. The mRNA level of PAR-2 in all the groups
was comparable, indicating tranexamic acid did not inﬂuence PAR-
2 expression. Together, these results indicate that tranexamic acid
inhibits PAR-2 activity, resulting in inhibition of Ca2þ mobilization.
Discussion
Rosacea is one of the most common inﬂammatory skin disorders.
The pathogenesis of rosacea is unknown. However, evidence sug-
gests that compromised epidermal permeability barrier could plays were measured as described in the materials and methods section. Chroma; on the
ating an obvious improvement of erythema severity. (B) While on the treated side, after
iﬁcantly (p < 0.05). (D) Stratum corneum hydration increased, indicating the impaired
es are shown in the ﬁgures (* p < 0.05).
Figure 2 Clinical pictures of two female patients before and after treatment. After a 2-week treatment, tranexamic acid improved the clinical manifestations of rosacea with fewer
inﬂammatory lesions. The right side was tranexamic acid-treated while the left side was vehicle-treated.
Table 1 Lesion assessment of rosacea patients before and after treatment. Lesion
count including papules and pustules were assessed by two experienced
dermatologists and the same investigator independently. The investigators'
assessment also revealed that the lesion counts decreased more signiﬁ-
cantly on the treated side than on the control side (p < 0.05).
Control side Treated side p2
Before After p1 Before After p1
6.5（0, 40） 2.5（0, 25） 0.000 6.5（2, 40） 1（0, 16） 0.000 0.043
Data are represented as median (minimum, maximum value).
p1 ¼ comparison of the score between Week 0 and Week 2 (Wilcoxon signed ranks
test).
p2 ¼ comparison of the score variation between control and treated side (Mann-
Whitney test).
Figure 3 Immunohistochemical ﬁndings of PAR-2 in rosacea and normal skin. PAR-2 stain
normal skin from two different donors (B, D  200,  400). Magniﬁcation bar ¼ 100 mm fo
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defective permeability barrier.20 Previous studies have demon-
strated that disruption of epidermal permeability barrier stimu-
lates cytokine expression, inﬂammatory cell inﬁltrate, LL-37
expression, as well as expression of vascular growth factor, all of
which are features of rosacea.21 In addition, rosacea exhibits a
higher level of SP activity, which activates PAR2. PAR-2 signaling
inﬂux of calcium ions in stratum granulosum keratinocytes could
inhibit lamellar body secretion, which is one of the mechanisms
that PAR-2 is involved in the regulation of permeability barrier
homeostasis.11 Activation of PAR-2 decreases E-cadherin adhe-
sion,22 whereas loss of E-cadherin function causes a defective
epidermal permeability barrier.23,24 Inhibition of SP by tranexamicing in rosacea skin from two different patients (A, C  200,  400), PAR-2 staining in
r 200 , and ¼ 40 mm for 400 .
Figure 4 Ca2þ mobilization responses to trypsin with or without tranexamic acid
treatment in HaCaT cells. HaCaT cells were pretreated with 200 mg/L tranexamic acid
and triggered by 100nM trypsin. The maximum signal was decreased and the peak
time was delayed in tranexamic acid group compared with the trypsin control group.
(A) Time response curves; (B) ﬂuorescence intensity.
S. Zhong et al. / Dermatologica Sinica 33 (2015) 112e117116acid [4-(aminomethyl)cyclohexane carboxylic acid,t-AMCHA], ac-
celerates barrier recovery and inhibits epidermal hyperplasia
induced by repeated barrier disruption.25
Logically, administration of tranexamic acid would beneﬁt ro-
sacea. Indeed, we demonstrate here that topical tranexamic acid
improves rosacea. The mechanisms by which tranexamic acid
beneﬁts rosacea could be due to the improvement of permeability
barrier function, likely resulting from the inhibition of SP. The
assumption is based on ﬁndings from present studies and previous
studies from others.26 First of all, both the expression levels of PAR-
2, as shown in present studies, and SP activity increases in rosacea.7
Secondly, inhibition of either SP or PAR-2 improves permeability
barrier homeostasis.6,27 As with PAR-2 inhibition, the present study
shows that pretreatment of keratinocytes with tranexamic acidFigure 5 Effect of tranexamic acid on the mRNA expression of PAR-2 in HaCaT cells.
Real time RT-PCR of PAR-2 in HaCaT cells after 24-hour tranexamic acid treatment.
Each data point represents the mean (± SEM) result from three independent experi-
ments. No statistical signiﬁcance was found.inhibits protease stimulated calcium mobilization. Thus, the
beneﬁcial effects of tranexamic acid on rosacea can be attributed to
inhibition of SP activity.
However, as a plasmin inhibitor, tranexamic acid suppresses
plasmin-induced angiogenesis, and also inhibits neovascularization
induced by basic ﬁbroblast growth factor (bFGF). It has been re-
ported that topical tranexamic acid could reduce erythema and
vessel numbers in the melasma lesion. We found in our study that
the erythema of rosacea was also reduced by tranexamic acid,
which might be caused by the antiangiogenic action of tranexamic
acid.28
The treatment of rosacea has been a big challenge for both pa-
tients and clinicians, mainly due to the lack of approaches targeting
pathogenic pathway. Although the pathogenesis of rosacea is un-
known, a line of evidence suggests that the development of rosacea
is driven by a defective permeability barrier. In addition to the in-
duction of pre-inﬂammatory cytokine releases, barrier disruption
increases the epidermal SP activity6 and LL-37 expression.29
Epidermal proteases, including kallikrein-related peptidases 5
and 7 (KLK5, KLK7), degrade LL-37 to different active fragments of
LL-37, including FA-29.7 The active forms of LL-37 cause erythema
and vasodilatation, as well as cytokine release.30,31 Moreover, LL-37
upregulates vascular endothelial growth factor expression.32
However, activation of PAR-2 by SP also undermined the perme-
ability barrier. The latter could exacerbate rosacea. The clinical
evidence that improvement of permeability barrier alone beneﬁts
rosacea33 also supports the pathogenic role of the permeability
barrier in rosacea. The putative pathogenic role of the permeability
barrier in rosacea and the mechanisms by which tranexamic acid
beneﬁts rosacea are illustrated in Figure 6.Figure 6 The possible pathogenic role of the permeability barrier in rosacea and the
mechanisms by which tranexamic acid beneﬁts rosacea. The impaired permeability
barrier function can increase serine protease (SP) activity, resulting from the elevation
of pH. Activation of SP activates SP-PAR2 and increases the production of active forms
of LL-37, which in turn induces inﬂammatory cell inﬁltrate and angiogenesis. Activa-
tion of SP-PAR2 pathway can cause further damage in the permeability barrier via the
inhibition of lamellar body secretion and E-cadherin adhesion. In addition, defective
permeability barrier alone could increase LL-37 expression and induce inﬂammation.
However, inﬂammation can worsen permeability barrier. Ultimately, inﬂammation and
defective permeability together lead to the development of rosacea. Tranexamic acid
beneﬁts rosacea via inhibition of SP activity, leading the reduction of inﬂammation and
improvement of permeability barrier function.
S. Zhong et al. / Dermatologica Sinica 33 (2015) 112e117 117In summary, the present study demonstrates that topical ap-
plications of tranexamic acid beneﬁt rosacea, likely due to the
improvement of the permeability barrier function. Epidermal
permeability barrier could be involved in the pathogenesis of ro-
sacea. Approaches targeting the pathogenic pathway could be an
optional therapy for rosacea.
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